RNXT Key Statistics, Chart & Performance
The current stock price of RNXT is 0.8904 USD. In the past month the price decreased by -23.42%. In the past year, price decreased by -31.86%.
RNXT Latest News, Press Relases and Analysis
RNXT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.17 | 403.52B | ||
| AMGN | AMGEN INC | 15.7 | 184.89B | ||
| GILD | GILEAD SCIENCES INC | 15.5 | 157.50B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.72 | 110.01B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.5 | 83.47B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 865.22 | 57.84B | ||
| INSM | INSMED INC | N/A | 43.60B | ||
| NTRA | NATERA INC | N/A | 32.85B | ||
| BIIB | BIOGEN INC | 10.9 | 26.75B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 21.99B | ||
| INCY | INCYTE CORP | 16.43 | 20.60B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About RNXT
Company Profile
RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a therapy platform to deliver chemotherapy. The company is headquartered in Mountain View, California and currently employs 10 full-time employees. The company went IPO on 2021-08-17. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
Company Info
RENOVORX INC
2570 W. El Camino Real, Ste. 320,
Mountain View CALIFORNIA US
CEO: Shaun R. Bagai
Employees: 10
Phone: 14088002649
RENOVORX INC / RNXT FAQ
What does RENOVORX INC do?
RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a therapy platform to deliver chemotherapy. The company is headquartered in Mountain View, California and currently employs 10 full-time employees. The company went IPO on 2021-08-17. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
What is the stock price of RENOVORX INC today?
The current stock price of RNXT is 0.8904 USD. The price increased by 2.89% in the last trading session.
Does RNXT stock pay dividends?
RNXT does not pay a dividend.
How is the ChartMill rating for RENOVORX INC?
RNXT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of RENOVORX INC (RNXT) based on its PE ratio?
RENOVORX INC (RNXT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.37).
Should I buy RNXT stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on RNXT.
Can you provide the ownership details for RNXT stock?
You can find the ownership structure of RENOVORX INC (RNXT) on the Ownership tab.
RNXT Technical Analysis
RNXT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RNXT. No worries on liquidiy or solvency for RNXT as it has an excellent financial health rating, but there are worries on the profitability.
RNXT Financial Highlights
Over the last trailing twelve months RNXT reported a non-GAAP Earnings per Share(EPS) of -0.37. The EPS increased by 36.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -78.16% | ||
| ROE | -100.22% | ||
| Debt/Equity | 0 |
RNXT Forecast & Estimates
10 analysts have analysed RNXT and the average price target is 5.61 USD. This implies a price increase of 530.05% is expected in the next year compared to the current price of 0.8904.